- OpenAI acquired Orchestra Bio, merging its AI agent platform into the Rosalind life sciences suite to accelerate drug development.
- Orchestra’s agents autonomously map how setbacks impact drug programs and compare potential responses, while scientists retain final authority.
- The deal follows Anthropic‘s $400 million purchase of Coefficient Bio in April, as AI labs compete to control drug development workflows.
OpenAI has acquired Orchestra Bio, a San Francisco startup whose AI agents help drug companies manage development programs, the ChatGPT maker announced Tuesday. “Our goal is to help scientists make discoveries and manage the work needed to turn them into treatments that reach patients sooner,” OpenAI said.
Orchestra’s team and platform will merge into Rosalind, OpenAI’s suite of AI tools for biologists and chemists, with terms undisclosed. The process of bringing a drug to market can take up to 15 years and cost over $2.6 billion, with fewer than 10% of candidates ever reaching patients.
Orchestra’s AI agents map how setbacks like failed manufacturing batches Ripple through programs and compare potential responses, while scientists retain final authority. Founded in fall 2022, Orchestra raised its seed round from Andreessen Horowitz, Definition Capital, Insight Partners, and 8VC, totaling about $20 million per Caplight data.
Meanwhile, Anthropic, OpenAI’s closest rival, bought AI biotech startup Coefficient Bio for roughly $400 million in April and launched Claude Science in June. OpenAI has also launched ChatGPT Health and acquired records startup Torch for a reported $100 million.
CFO Sarah Friar wrote in a January blog post that licensing, IP-based agreements, and outcome-based pricing will share in value created as AI moves into drug discovery. OpenAI recently offered eligible U.S. university labs up to 30 free seats for up to 12 months through a new Rosalind Academic Plan.
✅ Follow BITNEWSBOT on Telegram, Facebook, LinkedIn, X.com, and Google News for instant updates.
